Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3038 |
|
Actual shortage: | 236 (8%) | |
Anticipated shortage: | 15 (0%) | |
Avoided shortage: | 9 (0%) | |
Resolved: | 2778 (91%) | |
Discontinuation Reports |
356 |
|
To be discontinued: | 22 (6%) | |
Discontinued: | 334 (94%) | |
Reversed: | 0 (0%) | |
Late reports |
142 (4%) |
|
Overdue reports |
31 (11%) |
Shortage reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-GABAPENTIN | 300MG | CAPSULE | Resolved | 2018-04-02 | 2018-08-21 | 44497 |
APO-GABAPENTIN | 100MG | CAPSULE | Resolved | 2020-01-15 | 2020-02-10 | 103365 |
APO-GAIN LIQ 20MG/ML | 20MG | LIQUID | Resolved | 2017-04-12 | 2018-02-26 | 6554 |
APO-GATIFLOXACIN | 0.3% | SOLUTION | Resolved | 2023-09-28 | 2023-11-24 | 205486 |
APO-GATIFLOXACIN | 0.3% | SOLUTION | Resolved | 2024-03-27 | 2024-04-12 | 223555 |
APO-GEFITINIB | 250MG | TABLET | Resolved | 2022-04-14 | 2022-06-24 | 158819 |
APO-GEMFIBROZIL | 600MG | TABLET | Resolved | 2017-03-11 | 2019-11-26 | 610 |
APO-GEMFIBROZIL CAP 300MG USP | 300 MG | CAPSULE | Resolved | 2017-03-11 | 2019-06-12 | 607 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2017-10-17 | 2018-05-22 | 26159 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2018-05-01 | 2018-09-11 | 47680 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2020-02-13 | 2020-04-14 | 105997 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2020-09-02 | 2020-09-14 | 123561 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2022-01-28 | 2022-02-08 | 153780 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2022-12-16 | 2022-12-23 | 178760 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2023-04-21 | 2023-06-29 | 189988 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2024-01-26 | 2024-03-15 | 217487 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2024-03-01 | 2024-03-15 | 221093 |
APO-GLICLAZIDE | 80MG | TABLET | Actual shortage | 2024-04-05 | 2024-04-26 | 224583 |
APO-GLICLAZIDE | 80MG | TABLET | Actual shortage | 2024-04-19 | 2024-04-19 | 225799 |
APO-GLICLAZIDE MR | 60MG | TABLET (EXTENDED-RELEASE) | Resolved | 2017-11-21 | 2018-03-21 | 29960 |
Discontinuation reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-AMOXI CLAV 125MG/31.25MG PER 5ML | Discontinued | 2018-09-07 | 2018-09-15 | 60241 | ||
APO-AMOXI CLAV 125MG/31.25MG PER 5ML | Discontinued | 2018-12-21 | 2018-12-24 | 70347 | ||
APO-AMOXI CLAV 250MG/62.5MG PER 5ML | 250MG 62.5MG | POWDER FOR SUSPENSION | Discontinued | 2017-03-31 | 2017-03-31 | 4906 |
APO-AMOXI CLAV 250MG/62.5MG PER 5ML | Discontinued | 2019-05-13 | 2019-05-13 | 83981 | ||
APO-AMOXI SUGAR FREE | 125MG | POWDER FOR SUSPENSION | Discontinued | 2018-09-07 | 2018-09-15 | 60246 |
APO-AMOXI SUGAR FREE | 125MG | POWDER FOR SUSPENSION | Discontinued | 2018-09-07 | 2018-09-15 | 60249 |
APO-AMOXI SUGAR FREE | 250MG | POWDER FOR SUSPENSION | Discontinued | 2020-06-22 | 2020-06-22 | 118526 |
APO-ASA LD | 81MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60252 |
APO-ATENOL TAB 100MG | 100MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60261 |
APO-ATENOL TAB 50MG | 50MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60267 |
APO-ATOMOXETINE | 60MG | CAPSULE | Discontinued | 2018-09-07 | 2018-09-15 | 60273 |
APO-ATORVASTATIN | 10MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60276 |
APO-ATORVASTATIN | 20MG | TABLET | Discontinued | 2018-09-07 | 2019-02-13 | 60279 |
APO-ATORVASTATIN | 40MG | TABLET | Discontinued | 2018-09-07 | 2018-11-09 | 60282 |
APO-ATORVASTATIN | 80MG | TABLET | Discontinued | 2018-09-07 | 2018-12-29 | 60285 |
APO-BICALUTAMIDE | 50MG | TABLET | Discontinued | 2022-03-25 | 2022-05-13 | 157376 |
APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |